Model-informed precision dosing of beta-lactam antibiotics and ciprofloxacin in critically ill patients: a multicentre randomised clinical trial

[1] Bassetti M(2020)Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections Int J Antimicrob Agents 56 360-170

[2] Rello J(2021)Timing of antibiotic therapy in the ICU Crit Care 25 358-1336

[3] Blasi F(2017)Antimicrobial consumption, costs and resistance patterns: a two year prospective study in a Romanian intensive care unit BMC Infect Dis 17 162-1083

[4] Goossens H(2010)A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units Crit Care Resusc 12 1327-967

[5] Sotgiu G(2012)Introduction to drug pharmacokinetics in the critically III patient Chest 141 558-351

[6] Tavoschi L(2020)Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT) Crit Care 24 1072-153

[7] Zasowski EJ(2014)DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 957-655

[8] Arber MR(2020)Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients Eur J Clin Pharmacol 76 345-1143

[9] McCool R(2008)Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 136-451

[10] Patterson JV(2015)Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development Semin Respir Crit Care Med 36 629-2375

[1] Bassetti M(2020)Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections Int J Antimicrob Agents 56 360-170

[2] Rello J(2021)Timing of antibiotic therapy in the ICU Crit Care 25 358-1336

[3] Blasi F(2017)Antimicrobial consumption, costs and resistance patterns: a two year prospective study in a Romanian intensive care unit BMC Infect Dis 17 162-1083

[4] Goossens H(2010)A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units Crit Care Resusc 12 1327-967

[5] Sotgiu G(2012)Introduction to drug pharmacokinetics in the critically III patient Chest 141 558-351

[6] Tavoschi L(2020)Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT) Crit Care 24 1072-153

[7] Zasowski EJ(2014)DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58 957-655

[8] Arber MR(2020)Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients Eur J Clin Pharmacol 76 345-1143

[9] McCool R(2008)Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections Int J Antimicrob Agents 31 136-451

[10] Patterson JV(2015)Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development Semin Respir Crit Care Med 36 629-2375